Abstract library

17 results for "De Mestier".
#748 O6-Methylguanine-DNA Methyltransferase Deficiency in Neuroendocrine Tumors and Correlation with Response to Alkylating Agents (Temozolomide, Streptozotocin, Dacarbazine)
Introduction: Low O6-methylguanine-DNA methyltransferase (MGMT) expression is predictive of response to alkylants in some tumor types.
Conference: 10th Annual ENETS Conference (2013)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: MD thomas Walter
Keywords: MGMT
#806 Long-Term Prognosis of Pancreatic Neuroendocrine Tumors in Von Hippel-Lindau Disease
Introduction: Management of pancreatic neuroendocrine tumours (PNET) associated with von Hippel-Lindau (VHL) disease is challenging because of their malignant potential and poorly predictable prognosis.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Louis De Mestier
#824 Metachronous Functioning Syndromes in Sporadic Pancreatic Neuroendocrine Tumors (PNET)
Introduction: A metachronous functioning syndrome (MFS) may develop during the evolution of PNET initially functioning or not.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: Louis De Mestier
Authors: De Mestier L, Hentic O, Cros J, Brixi H, ...
#914 French Cohort of Familial Midgut Carcinoid Tumors
Introduction: Familial Midgut Carcinoid Tumors (FMCT) are a rare and poorly described entity defined by the occurrence of a midgut carcinoid tumor in at least two first-degree relatives.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: Louis De Mestier
#1067 Gemox or Alkylating Agents in Neuroendocrine Tumors? The Help of O6-Methylguanine-DNA Methyltransferase (MGMT) Status?
Introduction: Alkylating agents are the backbone chemotherapy in neuroendocrine tumors (NET). However, gemcitabine associated to oxaliplatine (gemox) has showed interesting activity in a small study.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Chemotherapy
Presenting Author: Anne-Sophie Dussol
#1096 How Manage Multiple Small Bowel Neuroendocrine Tumors?
Introduction: Multiple small bowel neuroendocrine tumors (SB-NET) represent 30% of SB-NET.
Conference: 12th Annual ENETS Conference (2015)
Category: Surgical treatment
Presenting Author: MD, PhD Thomas Walter
#1108 Regression of Paraneoplastic Optic Neuropathy Associated with Glucagonoma After Surgical Resection
Introduction: Glucagonomas-associated ocular manifestations have been exceptionally reported.
Conference: 12th Annual ENETS Conference (2015)
Category: Clinical cases/reports
Presenting Author: Lucie Defour
#1590 Treatment of Metastatic Pancreatic Neuroendocrine Tumors: Relevance of ENETS 2016 Guidelines
Introduction: The choice of first-line treatment of metastatic pancreatic neuroendocrine tumors (mP-NET) is mainly based on prognostic factors. ENETS-2016 guidelines proposed treatments according to 3 groups: Group-1, patients in whom all lesions could be removed; Group-2, patients with Ki67<10%, low tumor burden, no symptoms, and stable disease, for whom a watch-and-wait strategy or somatostatin analogs are proposed; Group-3, symptomatic patients or with Ki67>10% or significant tumor burden or progressive disease, for whom a systemic chemotherapy is proposed
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment – Chemotherapy, medical treatment - others
Presenting Author: Margaux Foulfoin
Keywords: pancreas, metastasis
#1828 5-Fluorouracile Plus Dacarbazine in Metastatic Digestive Neuroendoendocrine Tumors: Efficacy and Potential Biomarkers
Introduction: The 5-fluorouracile (5FU) + dacarbazine (DTIC) combination has been poorly evaluated in NET
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment – Chemotherapy, medical treatment - others
Presenting Author: Dr Louis de Mestier
#1901 Portal Hypertension-Related Digestive Hemorrhage in Patients with Pancreatic Neuroendocrine Tumors
Introduction: Pancreatic neuroendocrine tumors (pNET) can cause portal hypertension (PHT)
Conference: 14th Annual ENETS conference (2017)
Category: Clinical cases/reports
Presenting Author: Nelly Muller
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.